JP2022185501A - Composition for increasing muscle weight in postmenopausal women - Google Patents

Abstract

To provide techniques for increasing muscle mass in postmenopausal women, at least.SOLUTION: Provided is a composition for increasing muscle weight in postmenopausal women, comprising urolithins as an active ingredient.SELECTED DRAWING: None

Description

The present disclosure relates to compositions for increasing muscle mass in postmenopausal women.

A condition called sarcopenia, in which muscle mass decreases due to aging, disease, etc., resulting in decreased muscle strength and decreased physical function, has attracted attention. In the state of sarcopenia, symptoms such as slow walking and weak grip strength appear, and the risk of needing nursing care or support increases. Sarcopenia is a major factor in lowering the QOL (Quality of Life) and healthy life expectancy of the elderly, and prevention of sarcopenia is a major issue in Japan, which has become a super-aged society. In addition to sarcopenia, it is also a major issue to prevent frailty and locomotive syndrome, for which loss of muscle mass is one of the factors.

In addition, it is known that muscle mass decreases in menopausal women. Decrease in triceps surae muscle mass has also been reported in ovariectomized mice, which are animal models of menopausal women (Non-Patent Document 1).

On the other hand, various muscle mass increasing agents and the like have been developed. For example, a muscle mass-increasing composition containing lemon juice, oligosaccharic acid, and calcium as active ingredients has been developed (Patent Document 1). In the literature, in a group of postmenopausal middle-aged and elderly women who continuously ingested a test drink containing lemon juice, calcium oligosaccharide, fructose glucose solution, sweetener, and flavor, the muscle mass of the extremities after 5 months decreased to , was reported to have significantly increased compared to a group of postmenopausal middle-aged and elderly women who did not ingest the test drink.

On the other hand, compounds called urolithins are known. Urolithins represented by urolithin A and urolithin C are known as metabolites of ellagic acid derived from ellagitannins and the like contained in pomegranates, raspberries, blackberries, cloudberries, strawberries, walnuts and the like. Ellagitannins are classified as hydrolyzable tannins, and are known to be hydrolyzed in vivo and converted to ellagic acid when ingested by a subject.
So far, for example, regarding the production of urolithins in vivo, it has been clarified by analyzing urinary urolithins in rats that urolithins are produced from ellagitannins such as geraniin (non-patent literature). 2).
In addition, it has been reported that urolithins are detected in the urine of humans after ingestion of a pomegranate extract containing ellagitannins, mainly punicalagins, and that urolithin A and urolithin C are major ellagic acid metabolites. (Non-Patent Document 3).
These urolithins are known to have various physiological activities, and are expected to be used as materials for pharmaceuticals, cosmetics, and foods and drinks. For example, urolithin A has been reported to have antioxidant, anti-inflammatory, anti-glycation, and mitophagy-promoting effects (Non-Patent Documents 4-7).

JP 2018-153166 A

J. Home Econ. Jpn., Vol.47, No.12, 1173-1180 (1996) J. Agric. Food Chem., 56, 393-400 (2008) Mol. Nutr. Food Res., 58, 1199-1211 (2014) Biosci. Biotechnol. Biochem., 76, 395-399 (2012) J. Agric. Food Chem., 60, 8866-8876 (2012) Mol. Nutr. Food Res., 55, S35-S43 (2011) Nature Medicine, 22, 879-888 (2016)

An object of the present disclosure is at least to provide techniques for increasing muscle mass in postmenopausal women.

<1> A composition for increasing the muscle weight of postmenopausal women, comprising a urolithin as an active ingredient.
<2> The composition according to <1>, wherein the postmenopausal woman is a woman who takes a high-calorie diet.
<3> The composition according to <1> or <2>, wherein the muscle weight is the total weight of the triceps surae muscle weight and the plantar muscle weight.
<4> A composition for preventing postmenopausal women from becoming bedridden, containing urolithins as an active ingredient.
<5> The composition according to <4>, wherein the bedriddenness is prevented by an increase in muscle weight in the postmenopausal woman.
<6> The composition according to any one of <1> to <5>, wherein the urolithin is urolithin A, urolithin B, urolithin C, or urolithin H.
<7> The composition according to any one of <1> to <6>, which is a food or drink.
<8> The composition according to any one of <1> to <6>, which is a pharmaceutical.

The present disclosure may at least have the effect of providing techniques for increasing muscle mass in postmenopausal women. Moreover, the effect of providing the active ingredient for it can be produced.

Each configuration and combination thereof in each embodiment is an example, and addition, omission, replacement, and other modifications of configuration are possible as appropriate without departing from the gist of the present disclosure. This disclosure is not limited by the embodiments, but only by the scope of the claims.

One aspect of the present disclosure is a composition for increasing muscle mass in postmenopausal women comprising urolithins as active ingredients.

（式中、Ｒ１～Ｒ６は、それぞれ独立に、水酸基、水素原子又はメトキシ基を表す。）尚、通常、ウロリチン類とはＲ１～Ｒ６のうち１つ以上が水酸基である化合物を指すが、本明細書では、Ｒ１～Ｒ６のすべてが水素原子であるウロリチンＨもウロリチン類に含まれるものとする。 The urolithins used in this embodiment are represented by the following general formula (1).

(In the formula, R1 to R6 each independently represent a hydroxyl group, a hydrogen atom, or a methoxy group.) Generally, urolithins refer to compounds in which one or more of R1 to R6 are hydroxyl groups. In the specification, urolithin H in which all of R1 to R6 are hydrogen atoms is also included in urolithins.

As urolithins used in this embodiment, for example, as shown in Table 1, urolithin A, urolithin B, urolithin C, urolithin D, urolithin E, urolithin H, urolithin M3, urolithin M4, Urolithin M5, Urolithin M6, Urolithin M7, Isurolithin A, and the like.

The urolithins used in this embodiment are not particularly limited as long as they can increase the muscle weight of postmenopausal women, and one or more of them may be used. Urolithin A, urolithin B, urolithin C, or urolithin H are preferred.

The urolithins used in this embodiment may be commercially available ones or ones synthesized by chemical synthesis.
Commercially available urolithins include, for example, urolithin A, urolithin B, urolithin C, urolithin D, urolithin E (manufactured by Dalton Pharma), and urolithin H (manufactured by Sigma Aldrich, "6H-BENZO[C]CHROMEN-6 -ONE".) and so on.
In addition, as a synthesis method by chemical synthesis, a conventional method can be followed. In the case of urolithin A, for example, as described in the examples below, 2-bromo-5-methoxybenzoic acid and aluminum chloride are used as raw materials. A method of synthesizing urolithin A using

Alternatively, punicalagin, which is a type of ellagitannin, may be extracted from a plant and hydrolyzed to ellagic acid, or ellagic acid may be extracted and converted to urolithins using microorganisms.
The type of plant is not particularly limited, and examples include pomegranate, raspberry, blackberry, cloudberry, boysenberry, strawberry, walnut, and Chinese ginger. Among these, pomegranate, boysenberry, and gennoshoko are preferred, and pomegranate is more preferred, because of their high content of ellagitannin and/or ellagic acid.
Any one of these plants may be used alone, or two or more thereof may be used in combination. In addition, the extraction method and extraction conditions from the plant are not particularly limited, and conventional methods may be followed. For example, known extraction methods such as water extraction, hot water extraction, hot water extraction, alcohol extraction, and supercritical extraction can be used.

When solvent extraction is performed, the solvent can be, for example, water; lower alcohols such as methanol and ethanol; alcohols such as polyhydric alcohols such as propylene glycol and 1,3-butylene glycol (whether anhydrous or containing water) ); ketones such as acetone, esters such as diethyl ether, dioxane, acetonitrile and ethyl acetate, and xylene, preferably water and ethanol. Any one of these solvents may be used alone, or two or more thereof may be used in combination.
A method for hydrolyzing ellagitannins such as extracted punicalagin into ellagic acid is not particularly limited, but examples include methods of hydrolyzing with acids, enzymes, and microorganisms.
The method of converting ellagic acid to urolithins using a microorganism is not particularly limited, but for example, a known method described in Food Funct., 5, 8, 1779-1784 (2014) can be used. .

Although the obtained urolithins can be used as they are, they may be dried and used in the form of powder. Further, if necessary, the obtained urolithins may be subjected to purification, concentration treatment, and the like. As the purification treatment, filtration, adsorption using an ion exchange resin, activated carbon column, or the like, and decolorization treatment can be performed. As the concentration treatment, a conventional method such as an evaporator can be used.

In addition, the obtained urolithins (or purified products or concentrates) are subjected to a freeze-drying treatment to powderize them, or an excipient such as dextrin, cornstarch, gum arabic is added and powdered by a spray-drying treatment. You may pulverize according to a well-known method, such as a method. Further, after that, if necessary, it may be dissolved in pure water, ethanol, or the like and used.

The urolithins contained in the composition according to this aspect have the effect of increasing the muscle weight of postmenopausal women. That is, for example, postmenopausal women gain more muscle mass when they take urolithins than when they do not (or when they take a placebo or before they take urolithins). Therefore, urolithins can be used as active ingredients in compositions for increasing muscle mass in postmenopausal women.
The composition according to this aspect may be a mixture, and its components may be uniform or non-uniform. Also, in this disclosure, the terms "ingestion,""ingesting,""ingested," and the like, when used in pharmaceuticals, refer to "administration,""administered,""administered," and the like, respectively. can be replaced by the word

The subject who takes the composition according to this aspect is a postmenopausal female (postmenopausal human female). Menopause refers to the permanent cessation of menstruation as the ovaries become less active with age. The age at which a woman reaches menopause varies from individual to individual, but the postmenopausal woman in this embodiment is preferably a postmenopausal woman aged 40 or over, more preferably a postmenopausal woman aged 45 or over, and still more preferably. is a postmenopausal woman aged 50 or over, and even more preferably a postmenopausal woman aged 65 or over. In addition, in this specification, "elderly people" shall refer to a person 65 years or older. On the other hand, there is no upper limit to the age of the postmenopausal woman in this aspect, but for example, it may be up to the time of death or may be 100 years old or less.

Said postmenopausal woman is preferably a woman on a high calorie diet. "Ingestion of a high-calorie diet" means ingestion of a calorie amount of food that exceeds the amount of energy required for activity. Therefore, the term "high-calorie diet" refers to a diet that, when continuously ingested, causes body weight gain in a subject compared to continuous intake of a standard diet. Eating a high-calorie diet usually leads to weight gain. Examples of high-calorie diet include high-fat diet (not high-sucrose diet), high-sucrose diet (not high-fat diet), and “high-fat and high-sucrose diet (also referred to as high-fat and high-sucrose diet). ” and the like.

The muscles in this aspect are not particularly limited as long as they are muscles that increase weight in postmenopausal women who have ingested the composition according to this aspect.
Anti-gravity muscles include erector spinae, rectus abdominis, gluteus maximus, quadriceps femoris, triceps surae, and the like.
The muscles of the lower limbs include the lower limb girdle muscles, thigh muscles, cranial muscles, leg muscles, and the like. Among these, the leg muscles are preferred.
Examples of the leg muscles include the leg extensor muscle group, the peroneus muscle, the leg flexor muscle group, and the like. Among these, the muscles of the leg extensor group and the leg flexor muscles are preferable.
The muscles of the leg extensor group include the anterior tibialis, extensor digitorum longus (extensor digitorum longus), peroneus teris muscle, extensor hallucis longus, and the like.
The muscles of the leg flexor group include plantar muscle (plantar flexor), popliteal muscle, triceps surae (gastrocnemius, soleus, etc.), flexor digitorum longus, flexor posterior neck, flexor hallucis longus, and the like. Among these, plantar muscles (plantar flexors) and triceps surae (gastrocnemius, soleus, etc.) are preferred.
The muscle in this aspect may be one muscle or a plurality of muscles.

The muscle weight in this embodiment can be measured, for example, by (computer imaging, nuclear magnetic resonance imaging, dual-energy X-ray absorption, biological bioimpedance, ultrasound (echo examination), muscle area measurement, muscle perimeter, measurement, etc.).
In addition, when the muscle is the triceps surae muscle, the weight of the triceps surae muscle can be determined, for example, by measuring the crus circumference, which is the thickest part of the crus, and confirming the crus muscle volume from the crus circumference. .
The total weight of the weight of the triceps surae muscle and the weight of the plantar muscle may be obtained by adding the weight of the triceps surae muscle and the weight of the plantar muscle.

The muscle weight of postmenopausal women when ingesting the composition according to this aspect is the same as when the postmenopausal female does not ingest the composition according to this aspect (or when the placebo is ingested, or when the composition according to this aspect is taken). It is preferably 1.05-fold or more, more preferably 1.10-fold or more, and even more preferably 1.15-fold or more, based on the muscle weight (before ingestion). On the other hand, for example, it is preferable to increase by 2.0 times or less.

At this time, the muscle weight of the postmenopausal woman when not ingesting the composition according to this aspect (or when ingesting a placebo, or before ingesting the composition according to this aspect) is not particularly limited, but is preferably is 20 kg or more, more preferably 25 kg or more, still more preferably 30 kg or more, while is preferably 50 kg or less, more preferably 45 kg or less, still more preferably 40 kg or less.

The total weight of the triceps surae muscle weight and the plantar muscle weight of the postmenopausal woman when ingesting the composition according to this aspect is the same as when the postmenopausal woman does not ingest the composition according to this aspect ( or when ingesting a placebo or before ingesting the composition according to this aspect), based on the total weight of the triceps surae muscle weight and the plantar muscle weight, preferably increased by 1.05 times or more , more preferably 1.10 times or more, and more preferably 1.15 times or more. On the other hand, for example, it is preferable to increase by 2.0 times or less.

At this time, the weight of the triceps surae muscle and the plantar muscle when the postmenopausal woman does not ingest the composition according to this aspect (or when ingesting a placebo or before ingesting the composition according to this aspect) Although the total weight of the weight is not particularly limited, it is preferably 150 g or more, more preferably 200 g or more, and still more preferably 250 g or more, while preferably 500 g or less, more preferably 450 g or less, and still more preferably 400 g or less. is.

The composition according to this aspect has the effect of increasing muscle weight in postmenopausal women. Therefore, diseases, symptoms, symptoms or disorders that can be prevented or treated by increasing muscle mass in postmenopausal women (in the present disclosure, "diseases, symptoms, symptoms or disorders" may be described as "disease etc." ), etc., can be used for prevention or treatment. "Treatment" also includes improvement. Also, the subject post-menopausal female may have one or more medical conditions or the like. Examples of such diseases include bedridden, sarcopenia, frailty, locomotive syndrome, and the like.
Accordingly, another aspect of the present disclosure is, for example, a composition for preventing postmenopausal women from becoming bedridden, which contains urolithins as an active ingredient. Preferably, said bedriddenness is bedriddenness prevented by an increase in muscle weight of said postmenopausal woman.

The content of urolithins in the composition according to this aspect is appropriately set depending on the aspect of the composition. It is 0.1% by weight or more, and usually 50% by weight or less, preferably 25% by weight or less, more preferably 10% by weight or less.

The effective intake of the composition according to this aspect is appropriately set depending on the form of the composition, usage, subject, subject's age, sex, and other conditions. , is not particularly limited as long as the effect of increasing muscle weight is exhibited. The effective intake of the composition according to this aspect is usually 0.01 mg/50 kg body weight or more, preferably 0.1 mg/50 kg body weight or more, more preferably 1 mg/50 kg body weight or more, as the total amount of urolithins per day. Also, it is usually 5000 mg/50 kg body weight or less, preferably 500 mg/50 kg body weight or less, more preferably 50 mg/50 kg body weight or less.
In addition, the composition according to this aspect can be ingested once a day or in multiple doses. Also, it may be ingested once every several days or several weeks, but daily ingestion is preferred. Moreover, the intake period is preferably 11 weeks or longer.

The composition according to this aspect can be taken orally. However, it is not particularly limited as long as it is absorbed into the body.

Preferred embodiments of the composition according to this embodiment include foods and drinks (including supplements), pharmaceuticals, and the like. That is, as preferred embodiments that can be provided by the present disclosure, foods and drinks for increasing muscle weight in postmenopausal women containing urolithins as active ingredients, and for increasing muscle weight in postmenopausal women , foods and drinks containing urolithins as active ingredients for preventing bedridden postmenopausal women, and pharmaceuticals containing urolithins as active ingredients for preventing bedridden postmenopausal women, and the like.

When urolithins are used as food and drink ingredients, in addition to general food and drink, food for specified health uses, dietary supplement, functional food, food for the sick, food additives, etc. (These also include beverages.) can be used as The form of the food and drink may be a form other than the plant itself or the animal itself containing urolithins. It may be used for food in the form of a shape, granules, tablets, capsules, pastes, etc., and various foods such as processed meat foods such as ham and sausages, processed marine products such as kamaboko and fish cakes, breads, confectioneries, It may be used by adding to butter, milk powder and fermented milk products, or may be used by adding to beverages such as water, fruit juice, milk and soft drinks.

The food and drink can contain water, proteins, carbohydrates, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, flavors and the like as main ingredients. Examples of proteins include animal and plant proteins such as whole milk powder, skim milk powder, partially skim milk powder, casein, soybean protein, chicken egg protein and meat protein, hydrolysates thereof, and butter. Carbohydrates include saccharides, processed starch (dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like. Lipids include, for example, vegetable oils such as lard, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, hydrogenated oils, and transesterified oils. Examples of vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline. , folic acid, etc. Minerals include, for example, calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium, and whey minerals. Organic acids include, for example, malic acid, citric acid, lactic acid, and tartaric acid. These ingredients may be used in combination of two or more, and synthetic products and/or food and drink products containing these in large amounts may be used.

The food and drink can be produced according to a conventional method. In addition, the blending amount, blending method, and blending time for the urolithins can be appropriately selected. Furthermore, if necessary, it can be enclosed in an appropriate container such as a bottle, bag, can, box, pack, or the like.

The content of urolithins relative to the total amount of the food and drink is appropriately set depending on the form of the formulation and the like. 0.001% by weight or more. On the other hand, it is preferably 10% by weight or less, more preferably 1% by weight or less, and even more preferably 0.1% by weight or less.

The effective intake of the food and drink is appropriately set depending on the subject's age, weight, disease, etc., degree of disease, intake route, intake schedule, formulation form, etc. In postmenopausal women, there is no particular limitation as long as muscle weight increases. It is 50 kg or more and usually 5000 mg/50 kg or less, preferably 500 mg/50 kg or less, more preferably 50 mg/50 kg or less.
Moreover, the said food and drink can be ingested once a day or divided into multiple times. Also, it may be ingested once every several days or several weeks, but daily ingestion is preferred. Moreover, the intake period is preferably 11 weeks or longer.

When urolithins are used as materials for pharmaceuticals, either oral administration or parenteral administration can be adopted as the method of application as pharmaceuticals. For administration, the active ingredient can be mixed with a solid or liquid non-toxic pharmaceutical carrier suitable for administration methods such as oral administration, rectal administration, injection, etc., and administered in the form of a conventional pharmaceutical preparation. Examples of such formulations include solid formulations such as tablets, granules, powders and capsules, liquid formulations such as solutions, suspensions and emulsions, and freeze-dried formulations. It can be prepared by conventional means. Examples of non-toxic pharmaceutical carriers include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glycerides, polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acids, gelatin, Examples include albumin, water, physiological saline, and the like. In addition, if necessary, conventional additives such as stabilizers, wetting agents, emulsifiers, binders and tonicity agents can be added as appropriate.

The content of urolithins with respect to the total amount of the drug is appropriately set depending on the form of formulation, etc., but the total amount of urolithins is preferably 0.001% by weight or more, more preferably 0.01% by weight or more, and still more preferably 0% by weight. .1% by weight or more. On the other hand, it is preferably 50% by weight or less, more preferably 25% by weight or less, and even more preferably 10% by weight or less.

The effective dose of the drug is appropriately set depending on the subject's age, body weight, disease, severity, administration route, administration schedule, formulation form, etc. In postmenopausal women, there is no particular limitation as long as muscle weight increases. It is 50 kg or more and usually 5000 mg/50 kg or less, preferably 500 mg/50 kg or less, more preferably 50 mg/50 kg or less.
Also, the medicament may be administered once or multiple times a day. Also, daily administration is preferred, although once every few days or weeks administration may be possible. Moreover, the administration period is preferably 11 weeks or more.

The present disclosure can also provide the following aspects.
For example, the use of said urolithins for the manufacture of a composition for increasing muscle mass in postmenopausal women can be provided.
The urolithins can also be provided for use in the prevention or treatment of diseases that can be prevented or treated by increasing muscle mass in postmenopausal women.
Also, a method for preventing diseases that can be prevented or treated by increasing muscle weight, which comprises administering a prophylactically or therapeutically effective amount of the urolithins to a human or patient in need of such prevention or treatment. Or a method of treatment, wherein the human or patient is a postmenopausal female, can be provided.
Also provided is the use of said urolithins for increasing muscle mass in postmenopausal women.
The urolithins can also be provided for use in increasing muscle weight in postmenopausal women.
Also provided is a method for increasing muscle mass in postmenopausal women, comprising administering the urolithins to postmenopausal women.

Further, use of the urolithins for manufacturing a composition for preventing postmenopausal women from becoming bedridden can be provided.
The urolithins can also be provided for use in preventing bedridden postmenopausal women.
Also, a method for preventing bedriddenness, which comprises administering a prophylactically effective amount of the urolithins to a human or patient in need of prevention, wherein the human or patient is a postmenopausal woman; can be provided.
Further, use of the urolithins for preventing postmenopausal women from becoming bedridden can be provided.
In addition, the urolithins can be provided to prevent postmenopausal women from becoming bedridden.
Further, it is possible to provide a method for preventing postmenopausal women from becoming bedridden, comprising the step of administering the urolithins to postmenopausal women.

Examples are set forth below, but none of the examples are to be construed in a limiting sense.

(Preparation of urolithins)
5 g of 2-bromo-5-methoxybenzoic acid (manufactured by Wako Pure Chemical Industries, Ltd.) and 15 g of aluminum chloride were refluxed in 150 mL of chlorobenzene for 2.5 hours. After cooling, the reaction solution was transferred to ice water and extracted three times using 250 mL of diethyl ether. The resulting extract was concentrated under reduced pressure to distill off diethyl ether to obtain 4.2 g of 2-bromo-5-hydroxybenzoic acid. 2 obtained
3.9 g of -bromo-5-hydroxybenzoic acid and 3.9 g of resorcinol (manufactured by Tokyo Chemical Industry Co., Ltd.) were heated in 9 mL of 4 M NaOH aqueous solution at 60° C. for 30 minutes. After adding 1.8 mL of a 10% copper sulfate aqueous solution to this reaction solution, the mixture was further heated at 80° C. for 10 minutes. The produced precipitate was collected by filtration to obtain a white powder of urolithin A.

(Example 1)
As test animals, 7-week-old female ddy mice (Tokyo Experimental Animal Co., Ltd.) from which ovaries and oviducts had been removed were used. It is a mouse used as a postmenopausal animal model in the art.
A test group of 6 mice was fed a high-fat high-sucrose diet (HFS+UA) containing 0.05% by weight of urolithin A for 11 weeks. The diet, a high-fat high-sucrose diet (HFS), contained 28% fat and 30% sucrose by weight.
Each mouse was housed in an individual cage, given the above feed and tap water ad libitum, and kept for 11 weeks. The rearing environment was a temperature of 21±1°C, a humidity of 45-50%, and a light-dark cycle every 12 hours (light period: 7:00-19:00). After 11 weeks, three types of mixed anesthesia (including 7.5% Domitol (Nippon Zenyaku Kogyo, Fukushima, Japan), 8% Mitazolam (Sando Co., Ltd., Yamagata, Japan), and 10% Bentophenol (Meiji Seika Pharma Co., Ltd.)). After sacrificing the mice by collecting blood from the inferior vena cava under co-anesthesia with isoflurane and isoflurane, the triceps surae muscles and plantar muscles were isolated from the mice, and the weights of the isolated triceps surae muscles and plantar muscles were weighed. Weighed by

(Comparative example 1)
The experiment was carried out in the same manner as in Example 1, except that a high-fat high-sucrose diet (HFS) containing no urolithin A was used as feed.

(result)
The sum of the weight of the triceps surae muscle and plantar muscle weight measured in Example 1, where the total weight of the triceps surae muscle weight and plantar muscle weight measured in Comparative Example 1 is 100 The weight (relative value) was 118. That is, it was shown that ingestion of urolithin A increases the total weight of the triceps surae muscle weight and the plantar muscle weight in postmenopausal model animals.

Claims (8)

A composition for increasing muscle weight in postmenopausal women, comprising urolithins as an active ingredient. 2. The composition of claim 1, wherein the postmenopausal female is a female on a high calorie diet. 3. The composition of claim 1 or 2, wherein the muscle weight is the sum of the weight of the triceps surae muscle and the weight of the plantar muscle. A composition for preventing postmenopausal women from becoming bedridden, comprising urolithins as an active ingredient. 5. The composition of claim 4, wherein said bedriddenness is bedriddenness prevented by an increase in muscle weight of said postmenopausal woman. The composition according to any one of claims 1 to 5, wherein the urolithins are urolithin A, urolithin B, urolithin C, or urolithin H. The composition according to any one of claims 1 to 6, which is a food or drink. A composition according to any one of claims 1 to 6, which is a medicament.